SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...
Mammalian cell lines are crucial in the production of recombinant therapeutic proteins, vaccines and other clinically relevant drugs. A number of different lines are relied upon, but three in ...
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a ...
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...
Synthetic bio company Asimov agreed to collaborate with Cytiva to provide customers with an integrated offering for optimized biologics production. Access includes Asimov’s CHO Edge cell line ...
Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Gibco CHOvantage GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to support scalable manufacturing Thermo Fisher ...
Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ZURICH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results